GlassScriptPhysician profile
Jean Christophe Lapiere
NPI 1598760977
$1,377.08
in general payments reported to CMS, 2019-2025
15 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $57.94 · 2021: $49.36 · 2022: $209 · 2023: $454 · 2024: $155 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $375.50 | 2022-2023 | Otezla |
| Regeneron Healthcare Solutions, INC. | $317.65 | 2022-2025 | Libtayo |
| Almirall LLC | $137.55 | 2021-2025 | Klisyri |
| Galderma Laboratories, L.P. | $100.51 | 2019-2020 | |
| Pfizer INC. | $83.00 | 2019-2022 | |
| Biofrontera INC. | $78.40 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $52.21 | 2019-2024 | |
| Dermira, INC. | $41.61 | 2019 | |
| Leo Pharma INC. | $41.57 | 2019 | |
| Celgene Corporation | $37.80 | 2019 | |
| Genentech USA, INC. | $37.68 | 2019 | |
| Organogenesis INC. | $23.36 | 2023 | Puraply |
| Aclaris Therapeutics, INC. | $22.49 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.45 | 2024 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Christophe Lapiere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.